Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 2, 2008, Pages 258-259

  Bongiovanni, Marco ^a   Ranieri, Roberto ^a   Casana, Maddalena ^a   Tordato, Federica ^a   Cicconi, Paola ^a   Tincati, Camilla ^a   Bini, Teresa ^a   Monforte, Antonella D'Arminio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LETTER; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; VIREMIA;

EID: 38649107706     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318158befd     Document Type: Letter

References (13)

1. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
2. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med. 2000;160:2050-2056.
3. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005;40:1492-1499.
4. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type-2 diabetes. Hepatology. 2003;38:50-56.
5. Wang CS, Wang ST, Yao WJ, et al. Community-based study of hepatitis C virus infection and type-2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol. 2003;158:1154-1160.
6. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641.
7. Romero-Gomez M, Fernandez-Rodriguez C, Alonso S, et al. Sustained response in chronic hepatitis C reduces the risk to develop impaired fasting glucose and/or diabetes type 2. J Hepatol. 2006;44:548A.
8. Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother. 2004;15:287-297.
9. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.
10. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:401-411.
12. Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320-3325.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.